When pancreatic cancer cannot be removed surgically， patients frequently experience morbidity and death from progression of their primary tumor. Radiation therapy (RT) cannot yet substitute for an operation because radiation causes fatal bleeding and ulceration of the nearby stomach and intestines before achieving tumor control. There are no FDA-approved medications that prevent or reduce radiation-induced gastrointestinal injury. Here， we overcome this fundamental problem of anatomy and biology with the use of the oral EGLN inhibitor FG-4592， which selectively protects the intestinal tract from radiation toxicity without protecting tumors. A total of 70 KPC mice with autochthonous pancreatic tumors recei... More
When pancreatic cancer cannot be removed surgically， patients frequently experience morbidity and death from progression of their primary tumor. Radiation therapy (RT) cannot yet substitute for an operation because radiation causes fatal bleeding and ulceration of the nearby stomach and intestines before achieving tumor control. There are no FDA-approved medications that prevent or reduce radiation-induced gastrointestinal injury. Here， we overcome this fundamental problem of anatomy and biology with the use of the oral EGLN inhibitor FG-4592， which selectively protects the intestinal tract from radiation toxicity without protecting tumors. A total of 70 KPC mice with autochthonous pancreatic tumors received oral FG-4592 or vehicle control ± ablative RT to a cumulative 75 Gy administered in 15 daily fractions to a limited tumor field. Although ablative RT reduced complications from local tumor progression， fatal gastrointestinal bleeding was observed in 56% of mice that received high-dose RT with vehicle control. However， radiation-induced bleeding was completely ameliorated in mice that received high-dose RT with FG-4592 (0% bleeding， < 0.0001 compared with vehicle). Furthermore， FG-4592 reduced epithelial apoptosis by half ( = 0.002) and increased intestinal microvessel density by 80% compared with vehicle controls. EGLN inhibition did not stimulate cancer growth， as treatment with FG-4592 alone， or overexpression of HIF2 within KPC tumors independently improved survival. Thus， we provide a proof of concept for the selective protection of the intestinal tract by the EGLN inhibition to enable ablative doses of cytotoxic therapy in unresectable pancreatic cancer by reducing untoward morbidity and death from radiation-induced gastrointestinal bleeding. SIGNIFICANCE: Selective protection of the intestinal tract by EGLN inhibition enables potentially definitive doses of radiation therapy. This might allow radiation to be a surgical surrogate for unresectable pancreatic cancer. http://cancerres.aacrjournals.org/content/canres/79/9/2327/F1.large.jpg.
